...
首页> 外文期刊>Assay and drug development technologies >Efficient in silico assay of inhibitors of hepatitis C Virus RNA-dependent RNA polymerase by structure-based virtual screening and in vitro evaluation.
【24h】

Efficient in silico assay of inhibitors of hepatitis C Virus RNA-dependent RNA polymerase by structure-based virtual screening and in vitro evaluation.

机译:通过基于结构的虚拟筛选和体外评估,有效地计算机分析丙型肝炎病毒RNA依赖性RNA聚合酶抑制剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To identify a new protective or therapeutic intervention for hepatitis C virus (HCV) infection, we performed efficient structure-based virtual screening to identify novel inhibitory agents for HCV. To this end, we selected NS5B, an RNA-dependent RNA polymerase (RdRp), as the target for the treatment of HCV infection. To decipher the dockable nature of various RdRp X-ray crystals, we docked the crystal ligand (inhibitor) to the crystal receptor (enzyme). The accuracy of regeneration of the crystal pose indicates the amenability of the RdRp binding pocket for structure-based virtual screening. We also utilized a consensus scoring scheme to reduce false positives, thereby ensuring efficient virtual screening. In this study, each molecule that ranked in the top 1% among all screening molecules gained 1 consensus point in a scoring function. Thus, after virtual screening of 57,177 chemicals from the Maybridge Screening collection, 14 molecules gained 8 points across 11 scoring functions. One of them, an isoxazole, showed significant dose-dependent inhibition of HCV RdRp activity and replication. In this study, we have developed a structure-based virtual screening method using HCV RdRp for efficient identification of novel inhibitors.
机译:为了确定针对丙型肝炎病毒(HCV)感染的新的保护性或治疗性干预措施,我们进行了有效的基于结构的虚拟筛选,以鉴定针对HCV的新型抑制剂。为此,我们选择了RNA依赖性RNA聚合酶(RdRp)NS5B作为治疗HCV感染的靶标。为了破译各种RdRp X射线晶体的可停靠性质,我们将晶体配体(抑制剂)与晶体受体(酶)对接。晶体姿势再生的准确性表明,RdRp结合口袋可用于基于结构的虚拟筛选。我们还利用共识评分方案来减少误报,从而确保有效的虚拟筛选。在这项研究中,所有筛选分子中排名最高的1%的每个分子在得分功能上均获得了1个共识点。因此,在从Maybridge筛选收集中心对57,177种化学物质进行虚拟筛选后,14个分子在11个评分功能中获得了8分。其中之一,异恶唑,显示出对HCV RdRp活性和复制的显着剂量依赖性抑制。在这项研究中,我们已经开发了一种基于结构的虚拟筛选方法,使用HCV RdRp可以有效地鉴定新型抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号